Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Condition(s) studied

Investigational drug(s) / intervention(s)

Zoledronic Acid: 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement

Study summary

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.

Eligibility

Primary outcome measure(s)

• The endpoint for patient participation will be local recurrence — Followed for 2 years postoperatively for study end points
  Local recurrence of giant cell tumor of bone

Trial sites (16)